GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelluna ASA (FRA:7UM) » Definitions » E10

Zelluna ASA (FRA:7UM) E10 : €-0.36 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Zelluna ASA E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Zelluna ASA's adjusted earnings per share data for the fiscal year that ended in Dec. 2024 was €-0.494. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.36 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-03-17), Zelluna ASA's current stock price is € 0.1644. Zelluna ASA's E10 for the fiscal year that ended in Dec. 2024 was €-0.36. Zelluna ASA's Shiller PE Ratio of today is .


Zelluna ASA E10 Historical Data

The historical data trend for Zelluna ASA's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelluna ASA E10 Chart

Zelluna ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.36

Zelluna ASA Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.36

Competitive Comparison of Zelluna ASA's E10

For the Biotechnology subindustry, Zelluna ASA's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zelluna ASA's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelluna ASA's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zelluna ASA's Shiller PE Ratio falls into.



Zelluna ASA E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zelluna ASA's adjusted earnings per share data for the fiscal year that ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.494/134.8000*134.8000
=-0.494

Current CPI (Dec. 2024) = 134.8000.

Zelluna ASA Annual Data

per_share_eps CPI Adj_EPS
201512 0.000 100.900 0.000
201612 -0.208 104.400 -0.269
201712 -0.216 106.100 -0.274
201812 -0.352 109.800 -0.432
201912 -0.269 111.300 -0.326
202012 -0.378 112.900 -0.451
202112 -0.503 118.900 -0.570
202212 -0.468 125.900 -0.501
202312 -0.478 131.900 -0.489
202412 -0.494 134.800 -0.494

Add all the adjusted EPS together and divide 10 will get our e10.


Zelluna ASA  (FRA:7UM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Zelluna ASA E10 Related Terms

Thank you for viewing the detailed overview of Zelluna ASA's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Zelluna ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Zelluna ASA Headlines

No Headlines